Your browser doesn't support javascript.
loading
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States.
Merola, Joseph F; Tian, Haijun; Patil, Dhaval; Richardson, Craig; Scott, Amie; Chen, Yen-Hua; Kim, Nina; Hur, Peter; Armstrong, April W.
Afiliação
  • Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: jfmerola@bwh.harvard.edu.
  • Tian H; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Patil D; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Richardson C; Novartis Pharma AG, Basel, Switzerland.
  • Scott A; KMK Consulting, Inc, New York, New York.
  • Chen YH; KMK Consulting, Inc, New York, New York.
  • Kim N; The University of Texas at Austin, Austin, Texas; Baylor Scott and White Health, Temple, Texas.
  • Hur P; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Armstrong AW; Keck School of Medicine, University of Southern California, Los Angeles, California.
J Am Acad Dermatol ; 86(4): 748-757, 2022 04.
Article em En | MEDLINE | ID: mdl-34547358
BACKGROUND: Among patients in the United States with psoriasis (PsO), limited data exist on the incidence and prevalence of psoriatic arthritis (PsA) based on disease severity. OBJECTIVE: To assess the incidence, prevalence, and predictors of PsA among patients with PsO stratified by PsO severity using treatment type. METHODS: Incidence of PsA per 100 PsO patient-years (PY) and prevalence were assessed using the Optum electronic health records database. Incidence was assessed from PsO diagnosis and 1 year after PsO diagnosis overall and stratified by mutually exclusive treatment classes as a severity surrogate. RESULTS: The overall incidence of PsA was 2.9 (95% CI, 2.9-3.0) events per 100 PY. The incidence (95% CI) by severity surrogate was 2.1 (2.1-2.1), 9.9 (9.5-10.4), and 17.6 (16.9-18.3) events per 100 PY for patients with mild, moderate, and severe PsO as determined by receiving nonsystemics, nonbiologic systemic therapy, and biologics, respectively. When excluding patients diagnosed with PsA 1 year after PsO diagnosis, overall incidence was lower (1.7 [95% CI, 1.6-1.7] events per 100 PY), with similar trends for treatment-severity surrogates. LIMITATIONS: Results may not be generalizable to a wider population. CONCLUSION: The risk of developing PsA increased with disease severity and was highest in patients with the most severe PsO.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Artrite Psoriásica Tipo de estudo: Diagnostic_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Artrite Psoriásica Tipo de estudo: Diagnostic_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article